| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
| (30) |
Priority: |
16.07.2014 EP 14306153
|
| (43) |
Date of publication of application: |
|
16.10.2019 Bulletin 2019/42 |
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
15738359.7 / 3169341 |
| (73) |
Proprietor: TRANSGENE |
|
67400 Illkirch Graffenstaden (FR) |
|
| (72) |
Inventors: |
|
- SILVESTRE, Nathalie
67120 ERGERSHEIM (FR)
- GEIST, Michel
67170 BRUMATH (FR)
- RITTNER, Karola
67100 STRASBOURG (FR)
- MARCHAND, Jean-Baptiste
67210 OBERNAI (FR)
- THIOUDELLET, Christine
67000 STRASBOURG (FR)
|
| (74) |
Representative: Regimbeau |
|
20, rue de Chazelles
75847 Paris Cedex 17
75847 Paris Cedex 17 (FR) |
| (56) |
References cited: :
WO-A1-2009/065546
WO-A1-2019/178101
CN-A- 108 165 536
|
WO-A1-2014/047350
WO-A1-2020/049001
CN-A- 110 218 707
|
|
| |
|
|
- J D DIAS ET AL: "Targeted cancer immunotherapy with oncolytic adenovirus coding for
a fully human monoclonal antibody specific for CTLA-4", GENE THERAPY, 10 November
2011 (2011-11-10), XP055015331, ISSN: 0969-7128, DOI: 10.1038/gt.2011.176
- J. D. DIAS ET AL: "Targeted Chemotherapy for Head and Neck Cancer with a Chimeric
Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1", CLINICAL CANCER
RESEARCH, vol. 16, no. 9, 13 April 2010 (2010-04-13) , pages 2540-2549, XP055214478,
ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-2974
- T DU ET AL: "Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage
colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers", CANCER
GENE THERAPY, vol. 21, no. 8, 18 July 2014 (2014-07-18), pages 340-348, XP055214039,
ISSN: 0929-1903, DOI: 10.1038/cgt.2014.34
- CHRISTINE E ENGELAND ET AL: "CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic
Measles Virus Therapy", MOLECULAR THERAPY, vol. 22, no. 11, 26 August 2014 (2014-08-26),
pages 1949-1959, XP055158410, ISSN: 1525-0016, DOI: 10.1038/mt.2014.160
- MAXINE BAUZON ET AL: "Armed Therapeutic Viruses - A Disruptive Therapy on the Horizon
of Cancer Immunotherapy", FRONTIERS IN IMMUNOLOGY, vol. 5, 1 February 2014 (2014-02-01),
XP055214432, DOI: 10.3389/fimmu.2014.00074
- DON B GAMMON ET AL: "Vaccinia Virus-Encoded Ribonucleotide Reductase Subunits Are
Differentially Required for Replication and Pathogenesis", PL O S PATHOGENS (PRINT),
PUBLIC LIBRARY OF SCIENCE, US, vol. 6, no. 7, 8 July 2010 (2010-07-08), pages e1000984-1,
XP008150295, ISSN: 1553-7366, DOI: 10.1371/JOURNAL.PPAT.1000984
- KYLE G. POTTS ET AL: "Oncolytic Viruses in the Treatment of Bladder Cancer", ADVANCES
IN UROLOGY, vol. 2012, 1 January 2012 (2012-01-01), pages 1-11, XP055443442, ISSN:
1687-6369, DOI: 10.1155/2012/404581
- WOO YANGHEE ET AL: "Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the
Treatment of Pancreatic Cancer", JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, COLLEGE,
CHICAGO, IL, US, vol. 230, no. 4, 4 February 2020 (2020-02-04), pages 709-717, XP086103159,
ISSN: 1072-7515, DOI: 10.1016/J.JAMCOLLSURG.2019.12.027 [retrieved on 2020-02-04]
|
|
